Dimache G, Stoean C, Durbacă S, Croitoru M, Ionescu M, Nedelcu I N, Corbu I
Cantacuzino Institute, Bucharest.
Arch Roum Pathol Exp Microbiol. 1990 Jan-Mar;49(1):51-62.
Investigations of anti-tetanus response, in 404 subjects, most of them aged 60, being non-immunized for at least 10 years, stressed out the fact that 28.7% were not protected and 6.18% presented a protecting titer of 0.01 IU/ml, evaluated by "in vivo" protection test in mice. Some subjects were immunized with unadsorbed Tetanus vaccine (10 Lf/0.1 ml/dose) by i.d. route, using Jet-injector, and the others with adsorbed Tetanus vaccine (0.5 ml/dose), by i.m. route, using the needle and syringe. The vaccines were well tolerated and adverse reactions were not recorded. After 30 days, a single vaccine dose produced a protecting effect in 97.45% of non-protected subjects, belonging to i.d. immunized group, and also in 93.33% belonging to i.m. immunized group. 30 days after the administration of a second dose, protection set up in all subjects, no matter of vaccine type and administration route used. For a continuous reduction of tetanus morbidity, the authors suggest a specific periodical immunization of non-protected persons, selected by serological screening, using unadsorbed Tetanus vaccine, administered by i.d. route by means of the Jet-injector.
对404名受试者进行的抗破伤风反应调查显示,其中大多数人年龄为60岁,至少10年未接种疫苗。通过小鼠“体内”保护试验评估发现,28.7%的人没有受到保护,6.18%的人保护性滴度为0.01 IU/ml。一些受试者通过喷射注射器经皮内途径接种未吸附破伤风疫苗(10Lf/0.1ml/剂量),另一些受试者通过针头和注射器经肌肉途径接种吸附破伤风疫苗(0.5ml/剂量)。疫苗耐受性良好,未记录到不良反应。30天后,单剂疫苗对皮内免疫组中97.45%未受保护的受试者以及肌肉免疫组中93.33%未受保护的受试者产生了保护作用。在接种第二剂疫苗30天后,无论使用何种疫苗类型和接种途径,所有受试者均产生了保护作用。为持续降低破伤风发病率,作者建议通过血清学筛查选择未受保护的人群,使用未吸附破伤风疫苗,通过喷射注射器经皮内途径进行定期特异性免疫接种。